News

Partner companies' news

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022
SAN JOSE, Calif. , April 6, 2022 /PRNewswire/ --  Anixa Biosciences, Inc. [1] (NASDAQ: ANIX), a biotechnology company focused on the treatment and ...
Acorn Management Partners, Administrator
— April 2022 — 426 views ANIX

SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors
SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics [1] ( Nasdaq: SABS [2] ), (SAB), a clinical-stage biopharmaceutical compan...
Acorn Management Partners, Administrator
— April 2022 — 460 views SABS

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center
SAN JOSE, Calif. , March 30, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. [1] (NASDAQ: ANIX), a biotechnology company focused on the treatment and...
Acorn Management Partners, Administrator
— April 2022 — 468 views ANIX

SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results
SIOUX FALLS, S.D., March 29, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics [1] ( Nasdaq: SABS [2] ), (SAB), a clinical-stage biopharmaceutical compa...
Acorn Management Partners, Administrator
— April 2022 — 419 views SABS

Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC
SAN JOSE, Calif. , March 17, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. [1] (NASDAQ: ANIX), a biotechnology company focused on the treatment and ...
Acorn Management Partners, Administrator
— March 2022 — 488 views ANIX

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine
SAN JOSE, Calif., Jan. 25, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. [1]  (NASDAQ: ANIX), a biotechnology company focused on the treatment and ...
Acorn Management Partners, Administrator
— January 2022 — 529 views ANIX

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor
SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. [1]  (NASDAQ: ANIX), a biotechnology company focuse...
Acorn Management Partners, Administrator
— January 2022 — 469 views ANIX

Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— January 2022 — 454 views ARTH

Arch Therapeutics Announces Appointment of Guy Fish to the Board
FRAMINGHAM, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— January 2022 — 539 views ARTH

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference
SAN JOSE, Calif. , Dec. 16, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. [1]  (NASDAQ: ANIX), a biotechnology company focused on the treatment and ...
Acorn Management Partners, Administrator
— December 2021 — 475 views ANIX

Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
FRAMINGHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— December 2021 — 510 views ARTH

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant
SAN JOSE, Calif. and STUTTGART, Germany, Dec. 7, 2021 /PRNewswire/ --  Anixa Biosciences, Inc. [1]  (NASDAQ: ANIX), a biotechnology company focused...
Acorn Management Partners, Administrator
— December 2021 — 467 views ANIX

Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program
FRAMINGHAM, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“*Arch*” or the “*Company*”), a marketer and developer o...
Acorn Management Partners, Administrator
— December 2021 — 502 views ARTH

About us

Helping America invest in you:

Connecting your company stock with professional market participants.

One call at a time

Stay updated :

Participate on our social stream.

Our Blogs

Tags

Archives